Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Status:
Completed
Trial end date:
1998-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of epoetin alfa versus placebo in
reducing or preventing the need for transfusions in anemic patients with non-myeloid cancer
on non-platinum chemotherapy, and to investigate quality-of-life benefits associated with the
use of epoetin alfa. Epoetin alfa is a genetically engineered protein that stimulates red
blood cell production.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.